Incyte Corp (INCY) Gets a Buy Rating from Cowen & Co.

In a report released yesterday, Marc Frahm from Cowen & Co. maintained a Buy rating on Incyte Corp (INCY). The company’s shares closed yesterday at $68.32.

According to, Frahm is a 1-star analyst with an average return of -3.7% and a 33.3% success rate. Frahm covers the Healthcare sector, focusing on stocks such as Merrimack Pharmaceuticals, Adaptimmune Therapeutics, and Gritstone Oncology Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Incyte Corp with a $78.83 average price target.

See today’s analyst top recommended stocks >>

Based on Incyte Corp’s latest earnings release for the quarter ending September 30, the company reported a quarterly net profit of $29.18 million. In comparison, last year the company had a net profit of $36.05 million.

Based on the recent corporate insider activity of 68 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of INCY in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A.

Read More on INCY: